Dengue virus markers of virulence and pathogenicity

Future Virology

Volumn 4, Issue 6, 2009, Pages 581-589

  Rico Hesse, Rebeca ^a  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Dengue virus; Epidemiology; Evolution; Flavivirus; Viral pathogenesis

Indexed keywords

BIOLOGICAL MARKER; CD209 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; RNA POLYMERASE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; COMPUTER MODEL; CYTOKINE RELEASE; DENGUE; GENETIC VARIABILITY; HUMAN; INFECTION CONTROL; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; RECOMBINANT DNA TECHNOLOGY; REVIEW; RNA STRUCTURE; T LYMPHOCYTE ACTIVATION; VECTOR CONTROL; VIREMIA; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALIA; DENGUE VIRUS; DENGUE VIRUS GROUP; FLAVIVIRUS;

EID: 73949126952     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.09.51     Document Type: Review

References (69)

1. Halstead SB: Dengue. Lancet 370, 1644-1652 (2007).
2. Mathew A, Rothman AL: Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol. Rev. 225, 300-313 (2008).
3. Rosen L: Emperors new clothes revisited, or reflections on pathogenesis of dengue hemorrhagic-fever. Am. J. Trop. Med. Hyg. 26, 337-343 (1977).
4. Gubler DJ, Reed D, Rosen L, Hitchcock JC: Epidemiologic, clinical, and virologic observations on dengue in Kingdom-of-Tonga. Am. J. Trop. Med. Hyg. 27, 581-589 (1978).
5. Coffey LL, Mertens E, Brehin AC et al.: Human genetic determinants of dengue virus susceptibility. Microbes Infect. 11, 143-156 (2009).
6. Chen RF, Wang L, Cheng JT et al.: Combination of CTLA-4 and TGFβ1 gene polymorphisms associated with dengue hemorrhagic fever and virus load in a dengue-2 outbreak. Clin. Immunol. 131, 404-409 (2009).
7. Vejbaesya S, Luangtrakool P, Luangtrakool K et al.: TNF and LTA gene, allele, and extended HLA haplotype associations with severe dengue virus infection in ethnic Thais. J. Infect. Dis. 199, 1442-1448 (2009).
8. Marovich M, Grouard-Vogel G, Louder M et al.: Human dendritic cells as targets of dengue virus infection. J. Invest. Dermatol. Symp. Proc. 6, 219-224 (2001).
9. Cologna R, Rico-Hesse R: American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J. Virol. 77, 3929-3938 (2003).
10. Sun P, Fernandez S, Marovich MA et al.: Functional characterization of ex vivo blood myeloid and plasmacytoid dendritic cells after infection with dengue virus. Virology 383, 207-215 (2009). ■■ Very thorough study on the differences in infection rates and activation of primary human dendritic cell subsets.
11. Trent DW, Grant JA, Rosen L, Monath TP: Genetic-variation among dengue-2 viruses of different geographic origin. Virology 128, 271-284 (1983).
12. Repik PM, Dalrymple JM, Brandt WE, McCown JM, Russell PK: RNA fingerprinting as a method for distinguishing dengue-1 virus-strains. Am. J. Trop. Med. Hyg. 32, 577-589 (1983).
13. Rico-Hesse R: Microevolution and virulence of dengue viruses. Adv. Virus Res. 59, 315-341 (2003).
14. Kuno G, Chang GJ, Tsuchiya KR, Karabatsos N, Cropp CB: Phylogeny of the genus Flavivirus. J. Virol. 72, 73-83 (1998).
15. Wang E, Ni H, Xu R et al.: Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. J. Virol. 74, 3227-3234 (2000).
16. RicoHesse R, Harrison LM, Salas RA et al.: Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 230, 244-251 (1997).
17. Messer WB, Gubler DJ, Harris E, Sivananthan K, de Silva AM: Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg. Infect. Dis. 9, 800-809 (2003).
18. Cologna R, Armstrong PM, Rico-Hesse R: Selection for virulent dengue viruses occurs in humans and mosquitoes. J. Virol. 79, 853-859 (2005).
19. Kanakaratne N, Wahala WM, Messer WB et al.: Severe dengue epidemics in Sri Lanka, 2003-2006. Emerg. Infect. Dis. 15, 192-199 (2009).
20. Twiddy SS, Holmes EC, Rambaut A: Inferring the rate and time-scale of dengue virus evolution. Mol. Biol. Evol. 20, 122-129 (2003).
21. Vasilakis N, Weaver SC: The history and evolution of human dengue emergence. Adv. Virus Res. 72, 1-76 (2008).
22. Vasilakis N, Fokam EB, Hanson CT et al.: Genetic and phenotypic characterization of sylvatic dengue virus type 2 strains. Virology 377, 296-307 (2008). ■ Compares the genotype and phenotype of African and Malaysian dengue viruses with others.
23. Carpenter JE, Henderson EP, Grose C: Enumeration of an extremely high particle to pfu ratio for varicella zoster virus. J. Virol. 83(13), 6917-6921 (2009).
24. Mangada MNM, Igarashi A: Molecular and in vitro analysis of eight dengue type 2 viruses isolated from patients exhibiting different disease severities. Virology 244, 458-466 (1998).
25. Armstrong PM, Rico-Hesse R: Differential susceptibility of Aedes aegypti to infection by the American and southeast Asian genotypes of dengue type 2 virus. Vector Borne Zoonotic Dis. 1, 159-168 (2001).
26. van der Schaar HM, Rust MJ, Waarts BL et al.: Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J. Virol. 81, 12019-12028 (2007).
27. Kochel TJ, Watts DM, Halstead SB et al.: Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 360, 310-312 (2002).
28. Kochel TJ, Watts DM, Gozalo AS, Ewing DF, Porter KR, Russell KL: Crossserotype neutralization of dengue virus in Aotus nancymae monkeys. J. Infect. Dis. 191, 1000-1004 (2005).
29. Putnak JR, de la Barrera R, Burgess T et al.: Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Am. J. Trop. Med. Hyg. 79, 115-122 (2008).
30. Rodrigo WW, Alcena DC, Kou Z et al.: Difference between the abilities of human Fcγ receptor-expressing CV-1 cells to neutralize American and Asian genotypes of dengue virus 2. Clin. Vaccine Immunol. 16, 285-287 (2009).
31. Kraus AA, Messer W, Haymore LB, de Silva AM: Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J. Clin. Microbiol. 45, 3777-3780 (2007). γ Good comparison of dengue virus quantification techniques.
32. Martin NC, Pardo J, Simmons M et al.: An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies. J. Virol. Methods 134, 74-85 (2006).
33. Wu SJL, Grouard-Vogel G, Sun W et al.: Human skin Langerhans cells are targets of dengue virus infection. Nat. Med. 6, 816-820 (2000).
34. Pryor MJ, Carr JM, Hocking H, Davidson AD, Li P, Wright PJ: Replication of dengue virus type 2 in human monocyte-derived macrophages: comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein. Am. J. Trop. Med. Hyg. 65, 427-434 (2001).
35. Boonnak K, Slike BM, Marovich MA: Role of DC-SIGN and FcγRII in antibody dependent enhancement of dengue infection. Am. J. Trop. Med. Hyg. 75, 315-315 (2006).
36. Clyde K, Kyle JL, Harris E: Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J. Virol. 80, 11418-11431 (2006). ■■ Comprehensive review, including descriptions of the interactions of the 5′ and 3′ untranslated regions of the dengue viral genome.
37. Dejnirattisai W, Duangchinda T, Lin CL et al.: A complex interplay among virus, dendritic cells, T cells, and cytokines in dengue virus infections. J. Immunol. 181, 5865-5874 (2008).
38. Arevalo MT, Simpson-Haidaris PJ, Kou Z, Schlesinger JJ, Jin X: Primary human endothelial cells support direct but not antibody-dependent enhancement of dengue viral infection. J. Med. Virol. 81, 519-528 (2009).
39. Boonnak K, Slike BM, Burgess TH et al.: Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J. Virol. 82, 3939-3951 (2008).
40. Brown MG, King CA, Sherren C, Marshall JS, Anderson R: A dominant role for FcγRll in anti body-enhanced dengue virus infection of human mast cells and associated CCL5 release. J. Leukoc. Biol. 80, 1242-1250 (2006).
41. Jacobs M, Levin M: An improved endothelial barrier model to investigate dengue haemorrhagic fever. J. Virol. Methods 104, 173-185 (2002).
42. Carr JM, Hocking H, Bunting K et al.: Supernatants from dengue virus type-2 infected macrophages induce permeability changes in endothelial cell monolayers. J. Med. Virol. 69, 521-528 (2003).
43. Dewi BE, Takasaki T, Kurane I: In vitro assessment of human endothelial cell permeability: effects of inflammatory cytokines and dengue virus infection. J. Virol. Methods 121, 171-180 (2004).
44. Palmer DR, Sun PF, Celluzzi C et al.: Differential effects of dengue virus on infected and bystander dendritic cells. J. Virol. 79, 2432-2439 (2005).
45. Sun PF, Celluzzi CM, Marovich M et al.: CD40 ligand enhances dengue viral infection of dendritic cells: a possible mechanism for T cell-mediated immunopathology. J. Immunol. 177, 6497-6503 (2006).
46. Yauch LE, Shresta S: Mouse models of dengue virus infection and disease. Antiviral Res. 80, 87-93 (2008). ■ Most recent review on animal models of dengue disease.
47. Shultz LD, Ishikawa F, Greiner DL: Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7, 118-130 (2007).
48. Pearson T, Greiner DL, Shultz LD: Humanized SCID mouse models for biomedical research. Curr. Top. Microbiol. Immunol. 324, 25-51 (2008). ■■ Detailed description of how to prepare humanized mice and their use in understanding human disease.
49. Bente DA, Melkus MW, Garcia JV, Rico-Hesse R: Dengue fever in humanized NOD/SCID mice. J. Virol. 79, 13797-13799 (2005).
50. -/-)(c) (RAG-hu) mice. Virology 369, 143-152 (2007).
51. Bente DA, Rico-Hesse R: Models of dengue virus infection. Drug Discov. Today Dis. Models 3, 97-103 (2006).
52. Wang WK, Sung TL, Tsai YC, Kao CL, Chang SM, King CC: Detection of dengue virus replication in peripheral blood mononuclear cells from dengue virus type 2-infected patients by a reverse transcription-real-time PCR assay. J. Clin. Microbiol. 40, 4472-4478 (2002).
53. Bernard D, Peakman M, Hayday AC: Establishing humanized mice using stem cells: maximizing the potential. Clin. Exp. Immunol. 152, 406-414 (2008). ■■ Excellent discussion of promises and limitations in the preparation and use of humanized mice.
54. + human umbilical cord blood cells generate multiple lymphohematopoietic lineages in NOD-scid IL2rγ (null) mice. Exp. Biol. Med. (Maywood) 233, 997-1012 (2008).
55. Schmidt MR, Appel MC, Giassi LJ, Greiner DL, Shultz LD, Woodland RT: Human BLyS facilitates engraftment of human PBL derived B cells in immunodeficient mice. PLoS ONE 3, e3192 (2008).
56. Ward R, Davidson AD: Reverse genetics and the study of dengue virus. Future Virol. 3, 279-290 (2008). ■■ Good review of the use of recombinant viruses to understand dengue virology and the preparation of potential vaccines.
57. Polacek C, Friebe P, Harris E: Poly(A)-binding protein binds to the non-polyadenylated 3′ untranslated region of dengue virus and modulates translation efficiency. J. Gen. Virol. 90, 687-692 (2009).
58. Villordo SM, Gamarnik AV: Genome cyclization as strategy for flavivirus RNA replication. Virus Res. 139, 230-239 (2009). ■■ Excellent review of the interactions of the 5′ and 3′ untranslated regions and coding regions, to determine differences in replication.
59. Leitmeyer KC, Vaughn DW, Watts DM et al.: Dengue virus structural differences that correlate with pathogenesis. J. Virol. 73, 4738-4747 (1999).
60. Shurtleff AC, Beasley DWC, Chen JJY et al.: Genetic variation in the 3′ non-coding region of dengue viruses. Virology 281, 75-87 (2001). ■ Discusses how the phylogenies of the four serotype viruses using the 3′ untranslated region sequences correlate with genecoding region phylogenies; however, there are some errors in the compared sequences and, thus, in the conclusions.
61. Zhou Y, Mammen MP, Klungthong C et al.: Comparative analysis reveals no consistent association between the secondary structure of the 3′-untranslated region of dengue viruses and disease syndrome. J. Gen. Virol. 87, 2595-2603 (2006).
62. Alvarez DE, Ezcurra ALD, Fucito S, Gamarnik AV: Role of RNA structures present at the 3′ UTR of dengue virus on translation, RNA synthesis, and viral replication. Virology 339, 200-212 (2005).
63. Clyde K, Harris E: RNA secondary structure in the coding region of dengue virus type 2 directs translation start codon selection and is required for viral replication. J. Virol. 80, 2170-2182 (2006).
64. Alvarez DE, Filomatori CV, Gamarnik AV: Functional analysis of dengue virus cyclization sequences located at the 5′ and 3′ UTRs. Virology 375, 223-235 (2008).
65. Yu L, Nomaguchi M, Padmanabhan R, Markoff L: Specific requirements for elements of the 5′ and 3′ terminal regions in flavivirus RNA synthesis and viral replication. Virology 374, 170-185 (2008).
66. Koraka P, Williams MM, Djamiatun K et al.: RNA secondary structures in the proximal 3′ UTR of Indonesian dengue 1 virus strains. Virus Res. 142, 213-216 (2009).
67. Schroeder SJ: Advances in rna structure prediction from sequence: new tools for generating hypotheses about viral RNA structure-function relationships. J. Virol. 83(13), 6326-6334 (2009). ■■ Includes a listing of the available programs and the computing requirements to perform RNA folding predictions.
68. Zuker M: M-fold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406-3415 (2003).
69. Gultyaev AP, van Batenburg FH, Pleij CW: The computer simulation of RNA folding pathways using a genetic algorithm. J. Mol. Biol. 250, 37-51 (1995).